Work

Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real‐world experience

Year: 2022

Type: article

Source: British Journal of Haematology

DOI: 10.1111/bjh.18284

Authors: Naseema Gangat, Kristen McCullough, Aref Al‐Kali, Kebede H. Begna, Mrinal M. Patnaik, Mark R. Litzow, William Hogan, Mithun Shah, Hassan Alkhateeb, Abhishek Mangaonkar, James M. Foran, Jeanne M. Palmer, Animesh Pardanani, Ayalew Tefferi

Institutions: Mayo Clinic, Mayo Clinic in Florida, Mayo Clinic in Arizona

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281553780

FWCI: 2.795

Cites: 14

Cited by: 19

Related to: 10